BEWARE OF FAKE INSTITUTES WITH SIMILAR NAMES. blank    blank
banner articles

Measles-Rubella campaign

  Jan 31, 2018

Measles-Rubella campaign

Measles-Rubella campaign
India, along with ten other WHO South East Asia Region member countries, have resolved to eliminate measles and control rubella/congenital rubella syndrome (CRS) by 2020. In this direction, Ministry of Health & Family Welfare has initiated measles-rubella (MR) vaccination campaign in the age group of 9 months to less than 15 years in a phased manner across the nation. The campaign aims to cover approximately 41 crore children.
The Measles-Rubella campaign is a part of global efforts to reduce illness and deaths due to measles and rubella/CRS in the country. Measles immunization directly contributes to the reduction of under-five child mortality, and in combination with rubella vaccine, it will control rubella and prevent CRS.
The first phase of measles-rubella vaccination campaign has been successfully completed during February 2017 in five states, namely, Tamil Nadu, Karnataka, Goa, Lakshadweep and Puducherry. The campaign was carried out in schools, community centres and health facilities.
The campaign aims to rapidly build up immunity for both measles and rubella diseases in the community so as to knock out the disease, therefore, all the children should receive MR vaccine during the campaign.
In order to achieve maximum coverage during the campaign, multiple stakeholders have been involved, which includes, apart from Ministry of Health & Family Welfare, other Ministries, development partners, Lions clubs, professional bodies, for example, Indian Association of Paediatrics, Indian Medical Association, Civil Society Organizations etc.
All children from 9 months to less than 15 years of age will be given a single shot of Measles-Rubella (MR) vaccination during the campaign. Following the campaign, MR vaccine will become a part of routine immunization and will replace measles vaccine, currently given at 9-12 months and 16-24 months of age of child.